SS

Soumyadip Samanta

Active Director Director DIN 10813309
DIN 10813309 First appointment Oct 2024 Primary industry Software
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Soumyadip Samanta

Data last updated:

Soumyadip Samanta is a Director at Probe International Clinical Research Private Limited (since 2024). The company operates in Software.

DIN 10813309
Primary Designation Director
Industry Software
First Appointment 09 Oct 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director09 Oct 20242024Active

Directorship timeline

Open interactive timeline →
Probe International Clinical Research Private Limited
Premium access

Shareholding and investment profile for Soumyadip Samanta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Soumyadip Samanta

Soumyadip Samanta currently holds 1 directorship: Probe International Clinical Research Private Limited (Director, since 09 Oct 2024).

Soumyadip Samanta was first appointed on 09 Oct 2024 as Director at Probe International Clinical Research Private Limited.

The current boards of Soumyadip Samanta's companies include Amit Hazra (Probe International Clinical Research Private Limited), Bijoy Das (Probe International Clinical Research Private Limited), Liptan Das (Probe International Clinical Research Private Limited), Subhrojyoti Bhowmick (Probe International Clinical Research Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available